Casma: Tailoring autophagy targets to indications

How Third Rock portfolio company Casma is evaluating the entire autophagy pathway for a broad swath of diseases

Rather than focus on a single target, Casma is evaluating the entire autophagy pathway for a broad swath of diseases.

According to Casma Therapeutics Inc. CEO Keith Dionne, inappropriate accumulation of autophagy substrates is shared by seemingly disparate diseases, including Parkinson's disease, non-alcoholic steatohepatitis (NASH) and lysosomal storage disorder Pompe disease. The commonality of substrate accumulation presents the cellular recycling pathway as a common therapeutic target.

Third Rock Ventures, where Dionne was

Read the full 703 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE